This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the potential use of Sanofi and AstraZeneca’s newly approved RSV antibody drug for infants, nirsevimab, with a Pediatric Allergist

Ticker(s): SNY, AZN

Who's the expert?

Institution: Deaconess Clinic

  • Allergist and immunologist in practice since 2001
  • treats 13 patients/year with HAE
  • Familiar with Donidalorsen and has prescribed Haegarda, Orladeyo, and Takhzyro for patients with HAE

Interview Goal
This interview will focus on the recent FDA approval of Nirsevimab as an RSV preventative option for the broad newborn and infant population.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.